Compare Futu Holdings Ltd (FUTU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Novartis AG — how do they compare? Futu Holdings Ltd trades at $110.07 (market cap $15.25B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 17.6× Futu Holdings Ltd's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Novartis AG for 82 Days on average.
| FUTU | NVS | |
|---|---|---|
Market Cap | $15.25B | $268.57B |
Volume | 812,567 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $199.04 | $168.62 |
52-Week Low | $89.76 | $121.80 |
Typical Hold Time | 34 Days | 82 Days |
Enterprise Value | $15.59B | $309.89B |
Dividend Yield | 2.39% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $109.68, down 3.12% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $22.85B in 2025 with a net income margin of 49.62%, while valuation ratios like a P/E of 10.95 suggest potential undervaluation. Recent news includes Moomoo's partnership with X and a class action lawsuit deadline, adding mixed sentiment.
The outlook is cautiously optimistic due to robust earnings growth and analyst upside targets near 33%, but risks from legal issues and competitive pressures warrant monitoring. Investors may find value if the company executes on overseas expansion, though volatility from technical bearishness persists.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
